The value of serum osteoprotegerin levels in patients with angina like chest pain undergoing diagnostic coronary angiography

Ghaffari, Samad; Yaghoubi, Alireza; Baghernejad, Roya; Sepehrvand, Nariman; Sokhanvar, Sepideh; Haghjou, Amir Ghorbani

doi:10.5603/cj.2013.0071

Cited by 9 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of identified adipokines is permanently increasing, as well as their potential clinical diagnostic and prognostic value. These adipokines include mainly adiponectin [2-5], leptin [5], tumor necrosis factor (TNF) alpha [6,7], osteoprotegerin [8] interleukin 6 (IL-6) [9], resistin [10], interleukin 1 (IL-1) [11,12], apelin [13], visfatin [14], monocyte chemotactic protein-1 (MCP-1) [15,16], plasminogen activator inhibitor-1 (PAI-1) [17], retinol binding protein 4 (RBP4) [18] and several others.…”

Section: Introductionmentioning

confidence: 99%

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Fisman

Tenenbaum

2014

Cardiovasc Diabetol

201

157

View full text Add to dashboard Cite

Adiponectin is the most abundant peptide secreted by adipocytes, being a key component in the interrelationship between adiposity, insulin resistance and inflammation. Central obesity accompanied by insulin resistance is a key factor in the development of metabolic syndrome (MS) and future macrovascular complications. Moreover, the remarkable correlation between coronary artery disease (CAD) and alterations in glucose metabolism has raised the likelihood that atherosclerosis and type 2 diabetes mellitus (T2DM) may share a common biological background. We summarize here the current knowledge about the influence of adiponectin on insulin sensitivity and endothelial function, discussing its forthcoming prospects and potential role as a therapeutic target for MS, T2DM, and cardiovascular disease. Adiponectin is present in the circulation as a dimer, trimer or protein complex of high molecular weight hexamers, >400 kDa. AdipoR1 and AdipoR2 are its major receptors in vivo mediating the metabolic actions. Adiponectin stimulates phosphorylation and AMP (adenosin mono phosphate) kinase activation, exerting direct effects on vascular endothelium, diminishing the inflammatory response to mechanical injury and enhancing endothelium protection in cases of apolipoprotein E deficiency. Hypoadiponectinemia is consistently associated with obesity, MS, atherosclerosis, CAD, T2DM. Lifestyle correction helps to favorably modify plasma adiponectin levels. Low adiponectinemia in obese patients is raised via continued weight loss programs in both diabetic and nondiabetic individuals and is also accompanied by reductions in pro-inflammatory factors. Diet modifications, like intake of fish, omega-3 supplementation, adherence to a Mediterranean dietary pattern and coffee consumption also increase adiponectin levels. Antidiabetic and cardiovascular pharmacological agents, like glitazones, glimepiride, angiotensin converting enzyme inhibitors and angiotensin receptor blockers are also able to improve adiponectin concentration. Fibric acid derivatives, like bezafibrate and fenofibrate, have been reported to enhance adiponectin levels as well. T-cadherin, a membrane-associated adiponectin-binding protein lacking intracellular domain seems to be a main mediator of the antiatherogenic adiponectin actions. The finding of novel pharmacologic agents proficient to improve adiponectin plasma levels should be target of exhaustive research. Interesting future approaches could be the development of adiponectin-targeted drugs chemically designed to induce the activaton of its receptors and/or postreceptor signaling pathways, or the development of specific adiponectin agonists.

show abstract

Section: Introductionmentioning

confidence: 99%

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Fisman

Tenenbaum

2014

Cardiovasc Diabetol

201

157

View full text Add to dashboard Cite

show abstract

“…Serum OPG levels increased with the number of lesions on coronary angiography in 200 patients with CAD [ 11 ]. More recently, serum OPG levels correlated with CAD severity by angiographic Gensini score, and CV mortality was higher at midterm follow-up in patients with high OPG levels [ 25 ]. In our study, we further showed a strong association between the degree of complexity of the coronary lesions by SYNTAX score and the OPG level in patients with acute MI.…”

Section: Discussionmentioning

confidence: 99%

Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction

Cottin

Issa

Benalia

et al. 2021

JCM

View full text Add to dashboard Cite

Background. Osteoprotegerin (OPG), a glycoprotein of the tumour necrosis factor (TNF) superfamily, is one of the main biomarkers for vascular calcification. Aim. We aimed to evaluate the association between serum OPG levels and extent of coronary lesions in patients with acute myocardial infarction (MI). Methods. Consecutive patients hospitalized for an acute MI who underwent coronary angiography were included. SYNTAX score was calculated to assess the severity of coronary artery disease. The population was analysed in low (5 (3–6)), medium (11 (9–13)) and high (20 (18–23)) tertiles of SYNTAX score. Results. Among the 378 patients included, there was a gradual increase in age, rate of diabetes, anterior wall location, and a reduction in left ventricular ejection fraction across the SYNTAX tertiles. OPG levels significantly increased across the tertiles (962 (782–1497), 1240 (870–1707), and 1464 (1011–2129) pg/mL, respectively (p < 0.001)). In multivariate analysis, OPG [OR(CI95%): 2.10 (1.29–3.49) 0.003], were associated with the high SYNTAX group, beyond hypercholesterolemia, CV history and reduced glomerular filtration rate. Conclusion. We found an association between OPG levels and coronary lesions complexity patients with acute MI.

show abstract

“…Relationship between osteoprotegerin levels and stable coronary artery disease: Several studies have shown that OPG levels are predictive of CAD ( 11 , 12 , 42 , 43 ). Lieb et al ( 11 ) measured OPG levels in 3.250 Framingham Heart Study participants and found a positive association between circulating OPG levels (but not RANK-L) and CVD incidence and mortality.…”

Section: Osteoprotegerin: Structure Function and Metabolismmentioning

confidence: 99%

“…Some investigators have demonstrated a positive correlation between circulating OPG levels and the severity of atherosclerosis and the number of diseased vessels, especially in patients with type 2 DM ( 12 , 26 , 42 ). Ghaffari et al ( 43 ) reported a significant relationship between serum OPG levels and coronary artery stenosis. Furthermore, they found that major adverse cardiovascular events occurred more often in patients with higher baseline OPG levels.…”

Section: Osteoprotegerin: Structure Function and Metabolismmentioning

confidence: 99%

The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Özkalaycı¹,

Gülmez²,

Uğur-Altun³

et al. 2018

Balkan Med J

View full text Add to dashboard Cite

Cardiovascular disease is one of the most frequent causes of mortality and morbidity worldwide. Several variables have been identified as risk factors for cardiovascular disease. Recently, the role of receptor activator of nuclear factor kappa B, receptor activator of nuclear factor kappa B ligand, and the osteoprotegerin system has been recognized as more important in the pathogenesis of cardiovascular disease. Besides their roles in the regulation of bone resorption, these molecules have been reported to be associated with the pathophysiology of cardiovascular disease. There are conflicting data regarding the impact of osteoprotegerin, a glycoprotein with a regulatory role in the cardiovascular system. The aim of this review is to discuss the current knowledge and the role of osteoprotegerin in cardiovascular disease.

show abstract

The value of serum osteoprotegerin levels in patients with angina like chest pain undergoing diagnostic coronary angiography

Abstract: (Cardiol J 2013; 20, 3: 261-267)

Cited by 9 publications

References 18 publications

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction

The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Contact Info

Product

Resources

About